Matinas BioPharma Holdings (MTNB) Retained Earnings (2013 - 2026)
Matinas BioPharma Holdings (MTNB) reported Retained Earnings of -$212.7 million for Q1 2026, down 5.57% year-over-year from -$225.3 million in Q1 2025, and down 0.91% quarter-over-quarter from -$210.8 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Retained Earnings (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 14 years of Retained Earnings data on file, last reported at -$212.7 million in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$212.7 million, down 5.57% year-over-year; the trailing twelve-month figure through Mar 2026 was -$212.7 million (down 5.57% YoY), and the FY2025 annual result was -$210.8 million, down 5.49% from the prior year.
- Retained Earnings fell to -$212.7 million in Q1 2026 per MTNB's latest filing, from -$210.8 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$134000.0 in Q1 2024 and troughed at -$212.7 million in Q1 2026.
- A 5-year average of -$105.8 million and a median of -$175.6 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings jumped 99.44% in 2022, then tumbled 150258.21% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$824000.0 in 2022, then sank by 21207.4% to -$175.6 million in 2023, then fell by 13.81% to -$199.8 million in 2024, then declined by 5.49% to -$210.8 million in 2025, then declined by 0.91% to -$212.7 million in 2026.
- Business Quant data shows MTNB's Retained Earnings at -$212.7 million in Q1 2026, -$210.8 million in Q4 2025, and -$208.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | -212.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -212.71 Mn |
| Dec 31, 2025 | -210.79 Mn |
| Sep 30, 2025 | -208.88 Mn |
| Jun 30, 2025 | -206.73 Mn |
| Mar 31, 2025 | -201.48 Mn |
| Dec 31, 2024 | -199.82 Mn |
| Sep 30, 2024 | -191.39 Mn |
| Jun 30, 2024 | -187.12 Mn |
| Mar 31, 2024 | -134,000.00 |
| Dec 31, 2023 | -175.57 Mn |
| Sep 30, 2023 | -359,000.00 |
| Jun 30, 2023 | -514,000.00 |
| Mar 31, 2023 | -595,000.00 |
| Dec 31, 2022 | -824,000.00 |
| Sep 30, 2022 | -935,000.00 |
| Jun 30, 2022 | -754,000.00 |
| Mar 31, 2022 | -629,000.00 |
| Dec 31, 2021 | -145,000.00 |
| Sep 30, 2021 | -1,594.00 |
| Jun 30, 2021 | 51,000.00 |